Six of Nanjing Leads Biolabs' (HKG:9887) latest research results were selected to be presented at the 2026 annual meeting of the European Society for Medical Oncology.
Two were chosen for oral presentation, while four were selected for poster presentations covering extrapulmonary neuroendocrine carcinoma, biliary tract cancer, relapsed/refractory multiple myeloma, and other therapeutic areas.
The company has also been granted late-breaking abstract (LBA) eligibility and will submit the full LBA in September 2026.
The conference will be held in Madrid, Spain, from October 23 to 27.